Keyphrases
COVID-19
100%
Multisystem Inflammatory Syndrome in children (MIS-C)
67%
Vaccination
35%
Influenza Vaccine Effectiveness
27%
Vaccine Effectiveness
26%
Influenza
25%
Confidence Interval
22%
Serological Response
20%
Infected children
18%
Disease Burden
18%
Sickle Cell Disease
18%
Guardian
18%
Hospitalization
17%
Test-negative Design
13%
Child Hospitalized
13%
Antibody-dependent Cellular Cytotoxicity
13%
United States
12%
Childhood Vaccination
12%
COVID-19 Vaccination
12%
Kawasaki Disease
12%
Pediatric COVID-19
11%
COVID-19 Vaccine
11%
Vaccine Administration
11%
Pediatric
11%
Hospital Discharge
10%
Intravenous Immunoglobulin (IVIg)
10%
Methicillin-resistant Staphylococcus Aureus
10%
Immunoglobulin G
9%
Titer
9%
Pediatric Transplantation
9%
Chronic Obstructive Pulmonary Disease
9%
Household Contacts
9%
Circulating Follicular Helper T Cells
9%
Modified Vaccinia Virus Ankara
9%
Severe Acute Respiratory Syndrome coronavirus-2 Vaccine
9%
Older Adults
9%
Serologic
9%
HIV-infected children
9%
Infection Prevention
9%
Vaccine Attitudes
9%
Special Populations
9%
Concomitant Antibiotics
9%
Cryptococcal Infection
9%
Transplant Recipients
9%
Pre-pandemic
9%
Solid Organ Transplantation
9%
Congestive Heart Failure
9%
Cytokine Signature
9%
Infection Treatment
9%
Vaccination in children
9%
Medicine and Dentistry
COVID-19
77%
Serositis
49%
Severe Acute Respiratory Syndrome Coronavirus 2
49%
Household
27%
Influenza Vaccine
27%
Adolescence
27%
Pediatrics
27%
Infection
23%
COVID-19 Vaccine
18%
Sickle-Cell Disease
18%
Diseases
18%
Immunoglobulin G
15%
Cytokine
13%
Case-Control Study
12%
COVID-19 Vaccination
12%
Thrombocytopenia
10%
Transplantation
10%
Chronic Obstructive Pulmonary Disease
9%
Kawasaki Disease
9%
Vaccinia
9%
Plasmablast
9%
Respiratory Failure
9%
Solid Organ Transplantation
9%
Congestive Heart Failure
9%
Infectious Disease Treatment
9%
Disease Burden
9%
Reactogenicity
9%
Toxic Shock Syndrome
9%
Rotavirus Vaccine
9%
Pediatric Infection
9%
Influenza Vaccination
9%
T-Helper Cell
9%
Staphylococcus Aureus
9%
Memory B Cell
9%
T-Cell Response
9%
Methicillin Resistant Staphylococcus Aureus
9%
Osteomyelitis
9%
Immunoglobulin A
9%
T Follicular Helper Cell
9%
Health Outcomes
9%
Human parechovirus
9%
Influenza A Virus (H7N9)
9%
Receptor Binding
7%
Diagnosis
7%
Odds Ratio
7%
Disease Exacerbation
6%
Influenza
6%
Antibody Dependent Cellular Cytotoxicity
6%
Rotavirus
6%
Omicron Coronavirus Variant
6%
Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
27%
COVID-19
22%
Titer
20%
Influenza Vaccine
18%
Immunoglobulin G
17%
Influenza
17%
Antibody-Dependent Cell-Mediated Cytotoxicity
17%
Cytokine
13%
Immunogenicity
13%
Receptor Binding
13%
Neutralizing Antibody
12%
Staphylococcus Aureus
9%
Memory B Cell
9%
Modified Vaccinia Ankara
9%
Serology
9%
Filovirus
9%
Human Respiratory Syncytial Virus
9%
T-Helper Cell
9%
Parechovirus
9%
Respiratory Syncytial Virus Infection
9%
Immunoglobulin Blood Level
9%
Follicular B Helper T Cells
9%
Methicillin-Resistant Staphylococcus Aureus
9%
Plasmablast
9%
Human Immunodeficiency Virus
9%
AS03
9%
Human Parechovirus
9%
Booster Dose
9%
Rotavirus Vaccine
9%
Human Alphaherpesvirus 1
9%
Vaccination Schedule
9%
Adolescence
9%
Influenza A Virus (H7N9)
9%
Immunoglobulin A
9%
Cell Lysate
7%
Infectious Agent
7%
Herpes Simplex Virus
7%
Spike
7%
Enzyme Immunoassay
6%
Immunoglobulin G Antibody
6%
Virus Nucleocapsid
5%
Binding Antibody
5%
Immunoassay
5%